according to the present invention , synthetic and semi - synthetic bodies which have the property of mimicking in vivo apoptotic cells and / or apoptotic bodies in that they are taken up by cells of the patient &# 39 ; s immune system with accompanying beneficial effects such as inhibition of pro - inflammatory cytokines in vivo and / or promotion of anti - inflammatory cytokines are administered to patients . these synthetic and semi - synthetic bodies are three dimensional bodies having shapes and dimensions ranging from those resembling mammalian cells to shapes and dimensions approximating to apoptotic bodies produced by apoptosis of mammalian cells ( typically but not exclusively spheroidal , cylindrical , ellipsoidal including oblate and prolate spheroidal , serpentine , reniform , etc ., and from about 50 nanometers to about 500 microns in diameter ), and having phosphatidyl serine ( ps ) molecules on the surface thereof . such bodies are hereinafter referred to as “ ps - carrying bodies .” the term “ synthetic or semi - synthetic ps - carrying bodies ” refers to liposomes containing ps as well as up to 50 % non - ps components of the liposomes . the term “ non - liposomal synthetic bodies ” refers ps - carrying bodies that are not liposomes . as noted above , exposed ps on the membrane of a cell is known to play a key role in the clearance of apoptotic lymphocytes by macrophages . a receptor for ps is present on macrophages . a “ phosphatidylserine receptor ” or “ ps receptor ” is a receptor on an antigen presenting cell ( apc ), such as a macrophage , whose activity is blocked by soluble phosphatidylserine , either monomeric or oligomeric . it is contemplated that the ps receptor may also be present on other apcs , such as dendritic cells and b cells . it is understood that ps is a ligand of the ps receptor . according to this invention , ps - carrying bodies interact with a patient &# 39 ; s immune system , after administration to the patient by suitable means , presumably by engulfment by or other interaction with macrophages and / or dendritic cells or other antigen - presenting cells , to give substantially similar effects in terms of cytokine responses as are obtained when apoptotic cells / bodies are phagocytosed by macrophages . it is also significant that , in the present invention , ps - carrying bodies are acting as modifiers of the patient &# 39 ; s immune system , in a manner somewhat similar to that of a vaccine . accordingly , they are used in quantities and by administration methods to provide a sufficient localized concentration of the ps - carrying bodies at the site of injection to initiate the appropriate immune response . quantities of ps - carrying bodies appropriate for immune system modifying substances are generally not directly correlated with body size of the recipient animal and can , therefore , be clearly distinguished from drug dosages , which are designed to provide therapeutic levels of active substances in a patient &# 39 ; s bloodstream and tissues . drug dosages and are accordingly very much larger . it is contemplated that the patient may be a mammal , including but not limited to , humans and domestic animals such as cows , horses , pigs , dogs , cats , and the like . ps - carrying bodies have surface ps molecules . as a phospholipid , ps can form the membrane of a liposome , either as the sole constituent of the membrane or as a major or minor component thereof , with other phospholipids and / or membrane forming materials . liposomes , or lipid vesicles , are sealed sacs , in the micron or sub - micron range , the walls of which consist of layers of suitable amphiphiles . they normally contain an aqueous medium . it is understood that the ps - carrying body is not limited to a liposomal structure . phospholipids are amphiphilic molecules ( i . e . amphiphiles ), meaning that the compound comprises molecules having a polar water - soluble group attached to a water - insoluble hydrocarbon chain . the amphiphiles serving as the layers of the matrix have defined polar and apolar regions . the amphiphiles can include naturally occurring lipids such as ps , phosphatidylethanolamine , phosphatidylinositol , phosphatidylcholine , cholesterol , cardiolipin , ceramides and sphingomyelin , used alone or in admixture with one another . they can be synthetic compounds such as polyoxyethylene alkylethers , polyoxyethylene alkylesters and saccharosediesters . the present invention contemplates the use , as ps - carrying bodies , not only those liposomes having ps as a membrane constituent , but also liposomes having non - ps membrane substituents which carry on their external surface molecules of phosphoserine , either monomers or oligomers ( as distinguished from phosphatidylserine ), e . g ., chemically attached by chemical modification of the liposome surface , making the ps available for subsequent interaction with components of the patient recipient &# 39 ; s immune system . because of the inclusion of phosphoserine on the surface of such molecules , they are included within the definition of ps - carrying bodies . preferred ps - carrying bodies used in the present invention are liposomes constituted to the extent of 50 %- 100 % by weight of phosphatidylserine ( ps ), the balance being phosphatidylcholine ( pc ) or other such biologically acceptable phospholipid ( s ). more preferred are liposomes constituted by ps to the extent of 65 %- 90 % by weight , most preferably 70 %- 80 % by weight , with the single most preferred embodiment , on the basis of current experimental experience , being ps 75 % by weight , the balance being other phospholipids such as pc . they are prepared from mixtures of the appropriate amounts of phospholipids as starting materials , by known methods . methods of preparing liposomes of the appropriate size are known in the art and do not form part of this invention . reference may be made to various textbooks and literature articles on the subject , for example , the review article by yechezkel barenholz and daan j . a . chromeline , and literature cited therein , for example new , r . c . ( 1990 ), and nassander , u . k ., et al . ( 1990 ). the diameter of the ps liposomes of the preferred embodiment of this invention is from about 50 nanometers to about 1000 nanometers , more preferably from about 50 nanometers to about 500 nanometers . such preferred diameters will correspond to the diameters of mammalian apoptotic bodies . various alternatives to liposomes may be used as ps - carrying bodies in the present invention . these include particles , granules , microspheres or beads of biocompatible materials , natural or synthetic , such as polyethylene glycol , polyvinylprrolidone , polystyrene , etc ., polysaccharides such as hydroxethyl starch hydroxyethylcellulose , agarose and the like , as commonly used in the pharmaceutical industry . some such suitable substances for derivatization to attach the ps and , in the case of agarose , with ps attached , are commercially available , e . g . from polysciences , inc . 400 valley road , warrington , pa . 18976 , or from sigma aldrich fine chemicals . the beads may be solid or hollow , or filled with biocompatible material . they are modified as required so that they carry ps molecules on their surfaces . the ps - carrying bodies may be administered to the patient by any suitable means which brings them into operative contact with active ingredients of the patient &# 39 ; s immune system . the ps - carrying bodies may be suspended in a pharmaceutically acceptable carrier , such as physiological sterile saline , sterile water , pyrogen - free water , isotonic saline , and phosphate buffer solutions , as well as other non - toxic compatible substances used in pharmaceutical formulations . preferably , the ps - carrying bodies are constituted into a liquid suspension in a biocompatible liquid such as physiological saline and administered to the patient in any appropriate route which introduces it to the immune system , such as intra - arterially , intravenously or most preferably intramuscularly or subcutaneously . it is contemplated that the ps - carrying bodies may be freeze - dried or lyophilized which may be later resuspended for administration . this invention is also directed to a kit of part comprising lyophilized or freeze - dried ps - carrying bodies and a pharmaceutically acceptable carrier , such as physiological sterile saline , sterile water , pyrogen - free water , isotonic saline , and phosphate buffer solutions , as well as other non - toxic compatible substances used in pharmaceutical formulations . a preferred manner of administering the ps - carrying bodies to the patient is a course of injections , administered daily , several times per week , weekly or monthly to the patient , over a period ranging from a week to several months . the frequency and duration of the course of the administration is likely to vary from patient to patient , and according to the condition being treated , its severity , and whether the treatment is intended as prophylactic , therapeutic or curative . its design and optimization is well within the skill of the attending physician . the quantities of ps - carrying bodies to be administered will vary depending on the nature of the mammalian disorder it is intended to treat and on the identity and characteristics of the patient . it is important that the effective amount of ps - bodies is non - toxic to the patient , and is not so large as to overwhelm the immune system . when using intra - arterial , intravenous , subcutaneous or intramuscular administration of a liquid suspension of ps - carrying bodies , it is preferred to administer , for each dose , from about 0 . 1 - 50 ml of liquid , containing an amount of ps - carrying bodies generally equivalent to 10 %- 1000 % of the number of leukocytes normally found in an equivalent volume of whole blood or the number of apoptotic bodies that can be generated from them . generally , the number of ps - carrying bodies administered per delivery to a human patient is in the range from about 500 to about 500 , 000 , 000 (& lt ; 50 ng lipid ), more preferably from about 10 , 000 to about 10 , 000 , 000 , and most preferably from about 200 , 000 to about 2 , 000 , 000 . since the ps - carrying bodies are acting , in the process of the invention , as immune system modifiers , in the nature of a vaccine , the number of such bodies administered to an injection site for each administration is a more meaningful quantitation than the number or weight of ps - carrying bodies per unit of patient body weight . for the same reason , it is now contemplated that effective amounts or numbers of ps - carrying bodies for small animal use may not directly translate into effective amounts for larger mammals on a weight ratio basis . while it is not intended that the scope of the present invention should be limited by any particular theories of its mode of operation , the following is offered as a tentative explanation , for a better understanding of the ways an means by which the invention may be put into practice . it is postulated that antigen - presenting cells of the patient &# 39 ; s immune system , notably professional antigen presenting cells ( apcs ) including macrophages and dendritic cells , take up the ps - carrying bodies in a similar manner to the way in which they would take up apoptotic cells an apoptotic bodies . having taken up the ps - carrying bodies , the apcs induce an anti - inflammatory response promoting a change in the th cell population with an increase in the proportion of th2 cells and / or other regulatory / anti - inflammatory cell populations ( e . g ., tr1 cells ), and a decrease in th1 cells . th2 cells and other regulatory cells secrete anti - inflammatory cytokines such as interleukin - 10 , leading to reduced inflammation . the present invention is indicated for use in prophylaxis and / or treatment of a wide variety of mammalian disorders where t - cell function , inflammation , endothelial dysfunction and inappropriate cytokine expression are involved . a patient having or suspected of having such a disorder may be selected for treatment . “ treatment ” refers to a reduction of symptoms , such as , but not limited to , a decrease in the severity or number of symptoms of the particular disease or to limit further progression of symptoms . with respect to t - cell function ( t - cell mediated ) disorders , these may be autoimmune disorders including , but not limited to diabetes , scleroderma , psoriasis and rheumatoid arthritis . the invention is indicated for use with inflammatory allergic reactions , organ and cell transplantation reaction disorders , and microbial infections giving rise to inflammatory reactions . it is also indicated for use in prophylaxis against oxidative stress and / or ischemia reperfusion injury , ingestion of poisons , exposure to toxic chemicals , radiation damage , and exposure to airborne and water - borne irritant substances , etc ., which cause damaging inflammation . it is also indicated for inflammatory , allergic and t - cell - mediated disorders of internal organs such as kidney , lever , heart , etc . with respect to disorders involving inappropriate cytokine expression for which the present invention is indicated , these include neurodegenerative diseases . neurodegenerative diseases , including down &# 39 ; s syndrome , alzheimer &# 39 ; s disease and parkinson &# 39 ; s disease , are associated with increased levels of certain cytokines , including interleukin - 1β ( il - 1 ) ( see griffin wst et al . ( 1989 ); mogi m . et al . ( 1996 )). it has also been shown that il - 1β inhibits long - term potentiation in the hippocampus ( murray , c . a . et al . ( 1998 )). long - term potentiation in the hippocampus is a form of synaptic plasticity and is generally considered to be an appropriate model for memory and learning ( bliss , t . v . p . et al . ( 1993 )). thus , inappropriate cytokine expression in the brain is currently believed to be involved in the development and progression of neurodegenerative diseases . thus , the invention is indicated for the treatment and prophylaxis of a wide variety of mammalian neurodegenerative and other neurological disorders , including downs syndrome , alzheimer &# 39 ; s disease , parkinson &# 39 ; s disease , senile dementia , depression , multiple sclerosis , huntingdon &# 39 ; s disease , peripheral neuropathies , spinal cord diseases , neuropathic joint diseases , chronic inflammatory demyelinating disease , neuropathies including mononeuropathy , polyneuropathy , symmetrical distal sensory neuropathy , neuromuscular junction disorders , myasthenias and amyotrophic lateral sclerosis ( als ). regarding disorders involving endothelial dysfunction , the present invention is indicated for the treatment and prophylaxis of a wide variety of such mammalian disorders including , but not limited to , cardiovascular diseases , such as atherosclerosis , peripheral arterial or arterial occlusive disease , congestive heart failure , cerebrovascular disease ( stroke ), myocardial infarction , angina , hypertension , etc ., vasospastic disorders such as raynaud &# 39 ; s disease , cardiac syndrome x , migraine etc ., and the damage resulting from ischemia ( ischemic injury or ischemia - reperfusion injury ). in summary , it can be substantially any disorder that results from an inappropriately functioning endothelium . these examples show the effect of injecting various phosphatidylserine - containing liposomes of various sizes and compositions , and in various concentrations , on ear swelling in the murine contact hypersensitivity ( chs ) model , a th1 - mediated inflammatory reaction , an art - accepted model . for these experiments , female balb / c mice ( jackson laboratories ) age 6 - 8 weeks and weighing 22 - 25 g were used . phosophatidylserine ( ps ) containing liposomes of size 100 ± 20 nanometers were prepared as described above which had a phosphatidylserine content of 100 % ( i . e . made entirely of ps ). a stock suspension of liposomes containing 4 . 8 × 10 14 liposomes per ml was diluted with pbs to give an injection suspension containing 6 × 10 6 particles per ml , and each animal was injected with 50 μl of this suspension , containing 3 × 10 5 liposomes . test group a which received the liposomes comprised 25 animals in number . control group comprised 24 animals . the following experiments were run : on days 1 - 6 , mice of group a were injected with liposomes prepared from 100 % ps . liposomes were injected in 50 μl volume via intramuscular ( im ) injection , i . e . 300 , 000 liposomes per injection , for a total administration over the test period of 1 , 800 , 000 liposomes . mice of the control group received no liposomes , but were sensitized , challenged and tested in the same way as mice of group a , as described below . on day 1 , following liposome injection for that day , mice were anesthetized using 0 . 2 ml intraperitoneal ( ip ) injection of 5 mg / ml pentobarbital sodium . the abdominal skin of the mouse was sprayed with 70 % etoh . a blade was used to remove about a one - inch diameter of hair from the abdomen . the bare area was painted with 25 μl of 0 . 5 % 2 , 4 - dinitrofluorobenzene ( dnfb ) in 4 : 1 acetone : olive oil using a pipette tip . on day 6 , following liposome injection for that day , mice were challenged with dnfb as follows : 10 μl of 0 . 2 % dnfb was painted on the dorsal surface of the right ear with a pipette tip and 10 μl of vehicle was painted on the left ear with a pipette tip . on day 7 , 24 hours after challenge , each animal was anesthetized with halothane , and ear thickness ( in microns ) was measured using a peacock spring loaded micrometer . increase in ear swelling is used as a measure of chs response . data is expressed as the difference in the treated right ear thickness minus the thickness of the vehicle treated left ear . the significance of difference between the two experimental groups is determined by the two - tailed student t test . a value of p & lt ; 0 . 05 is considered significant . the results are presented below , and are also presented graphically on accompanying fig1 a bar graph of ear swelling , in microns . group control a mean ear swelling 10 . 75 8 . 52 ( microns ) standard deviation 3 . 03 2 . 77 standard error 0 . 62 0 . 55 p vs . control & lt ; 0 . 01 % inhibition vs . 20 . 70 control liposomes of size 100 ± 20 nanometers and containing different amounts of phosphatidyl serine , namely 90 %; 75 % and 50 %, with the remainder being phosphatidylcholine ( pc ), were prepared as described , from starting mixtures of the appropriate relative quantities of the respective phospholipids . using 4 different groups of animals , five mice per group , the following experiments were run . day 7 day day day day day day ( 24 group 1 2 3 4 5 6 hours ) b inject inject inject inject inject inject ear 90 % ps then then measured sensitize challenge c inject inject inject inject inject inject ear 75 % ps then then measured sensitize challenge d inject inject inject inject inject inject ear 50 % ps then then measured sensitize challenge positive sensi - challen - ear control tized ged measured ( untrea - ted animals the amounts and procedure for injection , the sensitization procedure , the challenge procedure and the results measurements were all as described in example 1 . the results are given below , in table 2 , and are graphically presented on fig2 . they show an apparent optimum ps concentration in the liposome of about 75 % by weight . again using the chs murine model described above , liposomes of size 100 ± 20 nanometers and containing 75 % ps and 25 % pc were injected into groups of mice according to the same protocol but at different dosage amounts i . e . different numbers of liposomes in each 50 μl injection . the numbers of liposomes per ml for the respective groups of animals , and the results obtained , using the same test and measurement procedures , were as follows : group e - 10 10 ( 10 animals ) average net ear swelling 11 . 10 ; sd 2 . 56 ; se 0 . 81 ; % of control 86 ; % reduction 14 ; p vs control 0 . 052 group f - 10 8 ( 15 animals ) average net ear swelling 8 . 93 ; sd 2 . 49 ; se 0 . 64 ; % of control 68 ; % reduction 32 ; p vs control & lt ; 0 . 0001 group g - 10 7 ( 5 animals ) average net ear swelling 6 . 20 ; sd 1 . 92 ; se 0 . 86 ; % of control 48 ; % reduction 52 ; p vs . control & lt ; 0 . 0001 group h - 10 6 ( 15 animals ) average net ear swelling 5 . 13 ; sd 2 . 17 ; se 0 . 56 ; % of control 40 ; % reduction 60 ; p vs . control & lt ; 0 . 0001 group j - 10 5 ( 5 animals ) average net ear swelling 7 . 60 ; sd 1 . 52 ; se 0 . 68 ; % of control 59 ; % reduction 41 ; p vs . control & lt ; 0 . 0001 group k - 10 4 ( 10 animals ) average net ear swelling 10 . 0 ; sd 1 . 05 ; se 0 . 33 ; % of control 78 ; % reduction 22 ; p vs . control 0 . 000128 . liposomes of 100 % ps of various sizes were prepared , and injected into groups of mice according to the protocol described in example 1 . the volumes of injection , numbers of liposomes per injection , procedures and measurements were also as described in example 1 . group average ear ( 3 animals liposome swelling , % each ) size ( nm ) of control sd se l 50 23 1 . 00 0 . 45 m 100 28 2 . 00 0 . 89 n 400 25 5 . 13 2 . 29 these results are presented graphically on accompanying fig4 . the liposomes are of fairly uniform size , with an approximate size range of ± 20 nm . agarose beads derivatized to carry phosphatidylserine ps on their surfaces were used in the murine contact hypersensitivity model described in example 1 , in place of the liposomes . the agarose beads were characterized by an average particle size of 45 - 165 microns and generally spherical in size ( sigma aldrich fine chemical , catalogue no . p3578 ) as a control , similar agarose beads free of ps were used ( sigma aldrich fine chemical , catalogue no . a9045 ). both the derivatized and the non - derivatized beads are commercially available from sigma chemical co . the agarose beads were suspended in pbs , and injected into the animals at a dosage of 300 , 000 beads , in 50 μl of suspension for each injection , according to the procedures and protocol described in example 1 . measurements of ear swelling were taken as described . five animals were used , in each of the experimental group and the control group . whereas the animals receiving underivatized agarose showed a mean net change in ear thickness as a result of the experiment of 7 . 8 μm ( sd 2 . 17 , sem 0 . 97 ), the corresponding number for the animals receiving ps - derivatized beads was 4 . 00 ( sd 2 . 92 , sem 1 . 30 , p vs agarose 0 . 047509 ), indicating significant activity of ps when attached to solid beads in accordance with the invention , as well as liposomal forms thereof . the results are presented graphically in fig5 . the hippocampus of the brain has been identified as a brain area which is especially vulnerable in degenerative conditions associated with cognitive dysfunction , such as alzheimer &# 39 ; s disease . in order to study the cellular and molecular mechanisms underlying cognitive function , the long - term potentiation ( ltp ) animal model is used . ltp is a form of synaptic plasticity that occurs in the hippocampal formation which has been proposed as a biological substrate for learning and memory ( bliss et al , nature 361 : 31 - 39 ( 1990 )). electrophysiology recording of ltp in rats in vivo followed by analysis of biochemical changes in hippocampal tissue harvested following recording provides a model which permits investigation of how the cellular events that underlie ltp may be altered in states associated with neuroinflammation such as aging , stress , alzheimer &# 39 ; s disease , and bacterial infection . systemic administration of lipopolysaccharide ( lps ), a component of the cell wall of gram - negative bacteria , provokes an activation of the immune system by inducing an increase in pro - inflammatory cytokines such as il - 1β . one example of a neuronal deficit induced by lps and il - 1β is the impairment of long term potentiation ( ltp ) in the hippocampus . an indicator of ltp is the mean slope of the population excitatory post - synaptic potential ( epsp ). upon tetanic stimulation , the epsp slope (%) rises sharply indicating increased synaptic activity , but lps - induced inhibition of ltp lessens this rise , and / or causes the epsp slope to revert more rapidly to base line , indicating that the increased sypnaptic activity is short - lived . accordingly measurements of the epsp slope (%) at timed intervals after tetanic stimulation can be used to reflect memory and the loss thereof following an inflammatory stimulus as well as inflammation in the hippocampus of the brain . ltp : 6 groups of 8 male wistar rats ( c . 300g ) were injected intramuscularly with saline carrier alone or with ps bodies , namely liposomes of 100 % ps , size 100 ± 20 nanometers in saline carrier . 9 × 10 5 liposomes in 150 μl of saline were injected into the rats on days − 14 , − 13 , and − 1 . on day 0 , rats were anesthetized with urethane ( 1 . 5 mg / kg , ip ) and injected with lps ( lipopolysaccharide ) ( 100 mg / kg i . p .) or saline as a control . after three hours , a bipolar stimulating electrode and a unipolar recording electrode were implanted in the perforant path and in the dorsal cell body of the dentate gyrus respectively . 0 . 033 hz test shocks were given and responses recorded for 10 minutes before and 45 minutes after tetanic stimulation ( 3 trains of stimuli delivered at 30 sec . intervals , 250 hz for 200 ms ) to induce lps . the rats were killed by decapitation ; the hippocampus , the tetanized and untetanized dentate gyri , the cortex and entorhinal cortex were dissected on ice , cross - chopped into slices and frozen in 1 ml of krebs solution containing 10 % dmso . effectiveness of blocking lps - induced inhibition of ltp was assessed from the electrophysiological recordings of neurotransmitter release in the tissue . the epsp slope (%) was followed for 10 minutes before and 40 minutes after tetanic stimulation . tissue from animals which had received a course of pretreatment with ps liposomes and an injection of lps exhibited a decline in epsp slope (%) of less than 5 % at 40 to 45 minutes after tetanic stimulation , whereas tissue from similarly injected animals without the ps liposome pretreatment course showed an approximate 25 % reduction over the same period . this is a clear indication the described pre - treatment with ps liposomes is exerting a neuroprotective effect . this is shown in fig6 bar graphs of epsp slope (%) of lps - injected , pretreated animal tissues ( right hand side ) and lps - injected , non - pretreated animal tissues ( left hand side ), at 40 - 45 minutes from tetanic stimulation ). the ** notation indicates significant difference from the respective saline control . the ++ notation indicates significant difference from the lps injected , non - pre - conditioned control . in addition , il - 1β concentration in the hippocampus was measured , by enzyme - linked immunosorbent assay techniques known in the art . the results are shown in fig7 bar graphs of il - 1β in pg / mg for control tissues which received no pretreatment with ps liposomes ( left hand side ) and tissues which received the pre - treatment described above ( right hand side ). the shaded bars represent results from tissues of animals given an lps injection , the clear bars those which received no such injection . it is clear that the preconditioning treatment has effectively inhibited the up - regulation of the inflammatory cytokine il - 1β ordinarily resulting from lps injection . similarly , reactive oxygen species ( ros ) formation in the hippocampus was investigated . ros was assessed in synaptosomes prepared from hippocampus by measuring dcf , the oxidized fluorescent product of dcfh - da . ros are known to destroy nerve cells . these results are similarly presented in fig8 again demonstrating the neuroprotective effect of the process of the present invention . further , the concentration of the anti - inflammatory cytokine il - 10 in the hippocampus was measured . il - 10 concentration was measured by enzyme - linked immunosorbent assay , and expressed as a percentage difference from the control . these results are presented , in a similar manner as fig7 and 8 , in fig9 . they show that , in tissue from animals which had not received pre - treatment according to the invention , lps injection caused a reduction in il - 10 content of about 30 % ( left side bars ) as compared with saline injection . in contrast , in tissue from animals subjected to the course of pre - treatment with ps liposomes as described , lps treatment caused an increase of about 45 % in the il - 10 content as compared with saline injection ( right side bars ). these results on il - 10 and il - 1β contents indicate significant anti - inflammatory effects in the hippocampus , following pre - treatment in accordance with the present invention . in summary , the results show that ps - carrying bodies are effective to block lps - induced ltp inhibition and neuroinflammation . all publications , patents and patent applications previously cited above are herein incorporated by reference in their entirety .
synthetic and semisynthetic bodies having a three - dimensional structure , sized and shaped to resemble apoptotic cells and apoptotic bodies , and having phosphatidyl serine molecules on the surface thereof , are administered to a patient , to alleviate a variety of disorders such as t - cell mediated disorders . the bodies are believed to trigger an apoptosis - like mechanism in the patient .